J H M Schellens

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. pmc Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
    N M G M Appels
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, Amsterdam 1066 EC, The Netherlands
    Br J Cancer 98:1951-8. 2008
  2. ncbi request reprint Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents
    Suzanne Leijen
    Department of Experimental Therapy, The Netherlands Caner Institute, Amsterdam, The Netherlands
    Curr Clin Pharmacol 5:186-91. 2010
  3. pmc A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    D S Boss
    Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Br J Cancer 106:1598-604. 2012
  4. ncbi request reprint Phase II and pharmacological study of oral docetaxel plus cyclosporin a in anthracycline pre-treated metastatic breast cancer
    Helgi H Helgason
    Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Curr Clin Pharmacol 9:139-47. 2014
  5. pmc Concise drug review: pazopanib and axitinib
    Robin M J M van Geel
    Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Oncologist 17:1081-9. 2012
  6. pmc Lapatinib for advanced or metastatic breast cancer
    Frans L Opdam
    The Netherlands Cancer Institute, Department of Clinical Pharmacology, Postbus 90203, 1006 BE Amsterdam, The Netherlands
    Oncologist 17:536-42. 2012
  7. pmc Long-term platinum retention after treatment with cisplatin and oxaliplatin
    Elke E M Brouwers
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    BMC Clin Pharmacol 8:7. 2008
  8. pmc Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients
    Marie Christine W Gast
    Department of Pharmacy and Pharmacology, Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    BMC Cancer 8:389. 2008
  9. ncbi request reprint [Management recommendations in patients with methotrexate intoxication]
    J H M Schellens
    Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, afd Medische Oncologie, Plesmanlaan 121, 1066 CX Amsterdam
    Ned Tijdschr Geneeskd 151:337-41. 2007
  10. pmc Part 1: background, methodology, and clinical adoption of pharmacogenetics
    Maarten J Deenen
    The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, The Netherlands
    Oncologist 16:811-9. 2011

Detail Information

Publications114 found, 100 shown here

  1. pmc Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
    N M G M Appels
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, Amsterdam 1066 EC, The Netherlands
    Br J Cancer 98:1951-8. 2008
    ..This study supports the rationale to implement biological effect studies in clinical trials with biologically active anticancer drugs to define optimal dosing regimens...
  2. ncbi request reprint Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents
    Suzanne Leijen
    Department of Experimental Therapy, The Netherlands Caner Institute, Amsterdam, The Netherlands
    Curr Clin Pharmacol 5:186-91. 2010
    ..Preliminary results show good tolerability and promising anti-cancer activity...
  3. pmc A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    D S Boss
    Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Br J Cancer 106:1598-604. 2012
    ....
  4. ncbi request reprint Phase II and pharmacological study of oral docetaxel plus cyclosporin a in anthracycline pre-treated metastatic breast cancer
    Helgi H Helgason
    Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Curr Clin Pharmacol 9:139-47. 2014
    ..This phase II study evaluates the anti-tumor activity, safety and pharmacokinetics of oral docetaxel in combination with CsA in women with advanced breast cancer...
  5. pmc Concise drug review: pazopanib and axitinib
    Robin M J M van Geel
    Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Oncologist 17:1081-9. 2012
    ....
  6. pmc Lapatinib for advanced or metastatic breast cancer
    Frans L Opdam
    The Netherlands Cancer Institute, Department of Clinical Pharmacology, Postbus 90203, 1006 BE Amsterdam, The Netherlands
    Oncologist 17:536-42. 2012
    ..Results of ongoing randomized phase III studies with lapatinib or trastuzumab in combination with taxanes as first-line agents for metastatic breast cancer as well as in the neoadjuvant and adjuvant settings are awaited...
  7. pmc Long-term platinum retention after treatment with cisplatin and oxaliplatin
    Elke E M Brouwers
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    BMC Clin Pharmacol 8:7. 2008
    ..The aim of this study was to evaluate long-term platinum retention in patients treated with cisplatin and oxaliplatin...
  8. pmc Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients
    Marie Christine W Gast
    Department of Pharmacy and Pharmacology, Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    BMC Cancer 8:389. 2008
    ..We conducted a retrospective follow-up study in which we investigated sera of high-risk primary breast cancer patients, to search for proteins predictive of recurrence free survival...
  9. ncbi request reprint [Management recommendations in patients with methotrexate intoxication]
    J H M Schellens
    Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, afd Medische Oncologie, Plesmanlaan 121, 1066 CX Amsterdam
    Ned Tijdschr Geneeskd 151:337-41. 2007
    ....
  10. pmc Part 1: background, methodology, and clinical adoption of pharmacogenetics
    Maarten J Deenen
    The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, The Netherlands
    Oncologist 16:811-9. 2011
    ..Opportunities for patient-tailored pharmacotherapy are highlighted...
  11. pmc Trastuzumab
    Annelies H Boekhout
    Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Oncologist 16:800-10. 2011
    ..Main toxicity is reduction in the left ventricular ejection fraction, which in a minority of patients can become symptomatic, but in many patients is at least partly reversible. Long-term safety needs to be further determined...
  12. ncbi request reprint Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate
    E E M Brouwers
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, and Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, The Netherlands
    J Mass Spectrom 41:1186-94. 2006
    ..50 ng l-1 to 1.00x10(5) ng l-1 in plasma ultrafiltrate for all three platinum compounds. The assay is now successfully used to support pharmacokinetic studies in cancer patients treated with cisplatin, carboplatin, or oxaliplatin...
  13. doi request reprint Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice
    J H Beumer
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Invest New Drugs 28:145-55. 2010
    ..Although hepatic trabectedin concentrations were not increased when P-gp was absent, mdr1a/1b(-/-) mice experienced more severe liver toxicity. P-gp plays a role in the in vivo disposition and toxicology of trabectedin...
  14. doi request reprint Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole
    L A Devriese
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Invest New Drugs 31:381-9. 2013
    ..3 %) achieved stable disease as best overall response. Conclusions The results indicate that eribulin mesylate can be safely co-administered with ketoconazole. Drug-drug interactions are not expected with other CYP3A4 inhibitors...
  15. doi request reprint Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
    M Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 69:25-33. 2012
    ..This study quantified the impact of drug pathway-associated genetic variants on the pharmacokinetics (PK) of gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)...
  16. ncbi request reprint Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours
    S A Veltkamp
    Division of Experimental Therapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 60:635-42. 2007
    ..Moreover, the tolerability and safety of the formulations was studied. In addition, single nucleotide polymorphisms in the multidrug resistance (MDR1) gene were determined...
  17. ncbi request reprint A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application
    S A Veltkamp
    Division of Experimental Therapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 59:43-50. 2007
    ..To investigate the pharmacokinetics, safety, and tolerability of a new oral formulation of paclitaxel containing the polymer polyvinyl acetate phthalate in patients with advanced solid tumors...
  18. pmc Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)
    Charlotte Van Kesteren
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Br J Clin Pharmacol 54:463-71. 2002
    ..The aim of this study was to develop and validate limited sampling strategies for the prediction of E7070 exposure in two different treatment schedules for phase II studies using the Bayesian estimation approach...
  19. doi request reprint Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors
    R L Oostendorp
    Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Invest New Drugs 28:163-70. 2010
    ..Continued dose-escalation was unlikely to yield any increase in exposure of indibulin. The formulation needs optimization to increase the systemic exposure upon oral administration...
  20. pmc Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
    H H Helgason
    Department of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066CX Amsterdam, and Faculty of Pharmaceutical Sciences, Utrecht University, The Netherlands
    Br J Cancer 95:794-800. 2006
    ..5 months and overall survival was 16 months. The pharmacokinetics revealed moderate inter- and low intrapatient variability. Weekly oral paclitaxel, combined with CsA, is active in patients with advanced breast cancer...
  21. doi request reprint Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment
    L A Devriese
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 70:823-32. 2012
    ..The aim of this study was to determine the plasma pharmacokinetics of eribulin mesylate in patients with solid tumors with mild and moderate hepatic impairment...
  22. doi request reprint Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
    M Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Lung Cancer 74:310-7. 2011
    ..The aim of this study was to assess the predictive value of tumor expression of nine genes on clinical outcome in patients with advanced NSCLC receiving platinum-gemcitabine chemotherapy...
  23. pmc Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
    T Kerbusch
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Br J Cancer 90:2268-77. 2004
    ....
  24. ncbi request reprint Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer
    J H Beumer
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    Invest New Drugs 23:429-36. 2005
    ..4% (3-h administration schedule). The excretion of unchanged trabectedin is very low both in faeces and in urine (< 1% of dose). In conclusion, trabectedin is extensively metabolised and principally excreted in the faeces...
  25. pmc A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer
    S A Veltkamp
    Division of Experimental Therapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
    Br J Cancer 95:729-34. 2006
    ..Remarkably, the SMEOF#3 formulation resulted in a significantly lower T(max) than orally applied Taxol, probably due to the excipients in the SMEOF#3 formulation resulting in a higher absorption rate of paclitaxel...
  26. doi request reprint Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin
    E E M Brouwers
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    Anal Bioanal Chem 391:577-85. 2008
    ..The advantages of the presented ICP-MS technique were demonstrated by the analysis of PBMCs, normal gastric tissue, and gastric tumour tissue of patients treated with cisplatin...
  27. ncbi request reprint PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression
    A S Zandvliet
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Clin Pharmacol Ther 83:829-39. 2008
    ..The combination of 550 mg/m(2) indisulam and 1,250 mg/m(2) capecitabine twice daily was considered safe...
  28. ncbi request reprint Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer
    C M F Kruijtzer
    The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Oncol 14:197-204. 2003
    ..Two doses of oral paclitaxel on 1 day in combination with CsA resulted in higher systemic exposure than single dose administration...
  29. pmc Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor
    F J P Hoebers
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 61:1075-81. 2008
    ..In this study, the formation of cisplatin-DNA adducts after concurrent cisplatin-radiation and the relationship between adduct-formation in primary tumor tissue and normal tissue were investigated...
  30. doi request reprint Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma
    S F Teunissen
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 878:2353-62. 2010
    ..The developed method is simple, robust and reproducible. The applicability of the method was demonstrated and the assay could be successfully used to support in vivo toxicokinetics studies of PhIP and N-OH-PhIP in mice...
  31. pmc A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
    W S Siegel-Lakhai
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Br J Cancer 98:1320-6. 2008
    ..The higher incidence of toxicities observed during cycle 2 can be explained by a time-dependent pharmacokinetic drug-drug interaction...
  32. ncbi request reprint Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer
    M Crul
    Netherlands Cancer Institute and Academic Medical Centre, Amsterdam, The Netherlands
    J Clin Oncol 20:2726-35. 2002
    ..To determine the maximum-tolerated dose, toxicities, and pharmacokinetics of R115777, a farnesyl transferase inhibitor, when administered continuously via the oral route...
  33. ncbi request reprint Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors
    I E L M Kuppens
    Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX Amsterdam, The Netherlands
    Invest New Drugs 25:227-35. 2007
    ..This study is continued, evaluating indibulin administered as capsules on the recommended dose level of 60 mg daily for 14 days...
  34. pmc Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
    W S Siegel-Lakhai
    The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Br J Cancer 93:1222-9. 2005
    ..i.d. in combination with gemcitabine 1000 mg m(-2) and cisplatin 75 mg m(-2). This combination showed evidence of antitumour activity and warrants further evaluation in a phase II setting...
  35. pmc Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer
    J H M Schellens
    The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Br J Cancer 88:814-21. 2003
    ..Randomised studies are needed to determine whether the adaptive dosing strategy results in better efficacy than standard dosing...
  36. doi request reprint Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices
    A C Dubbelman
    Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 887:25-34. 2012
    ..At the other concentrations the accuracies were within ±15% of the nominal concentration with CV values below 15%. The developed methods have successfully been applied in a mass balance study of E7080...
  37. pmc Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
    D S Boss
    Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Oncol 21:884-94. 2010
    ..Three phase I studies assessed the clinical safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5438 when administered in different dosing schedules...
  38. ncbi request reprint Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)
    I E L M Kuppens
    Department of Medical Oncology, Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 55:72-8. 2005
    ..Furthermore, the safety of combined treatment was determined and whether known functional genetic polymorphisms of the MDR1 gene could be associated with variability in docetaxel pharmacokinetics was also investigated...
  39. pmc Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
    J H Beumer
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Invest New Drugs 25:327-34. 2007
    ..Future studies should focus on structural elucidation of ixabepilone metabolites and characterization of their activities...
  40. pmc Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies
    Ron J Keizer
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    AAPS J 13:230-9. 2011
    ..Moderate inhibition of α(2)-integrin expression corresponded to tumor stasis in mice, and similar levels could be reached in patients with the dose level of 100 mg qd...
  41. ncbi request reprint Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer
    C M F Kruijtzer
    Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 20:4508-16. 2002
    ..A phase II study was performed to assess the efficacy and toxicity of oral cyclosporine (CsA) plus paclitaxel in advanced non-small-cell lung cancer (NSCLC)...
  42. ncbi request reprint A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry
    A G Lankheet
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 877:3625-30. 2009
    ..57%) and precision (CV < or = 8.81%). This method has been used to determine plasma vatalanib concentrations in patients with advanced solid tumor, enrolled in a phase I pharmacokinetic trial with the drug...
  43. ncbi request reprint Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry
    E Stokvis
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    J Mass Spectrom 38:548-54. 2003
    ..ES-285 was stable during all steps of the assay. Thus far this method has been used successfully to analyze over 500 samples in pre-clinical trials, and will be implemented in the planned clinical phase I studies...
  44. doi request reprint From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies
    S L W Koolen
    Slotervaart Hospital, Department of Pharmacy and Pharmacology, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    J Clin Pharmacol 52:370-80. 2012
    ..Subsequently, the model was used to predict human exposure using allometric scaling and this was compared with clinical trial data. This model led to adequate predictions of docetaxel exposure in humans...
  45. doi request reprint Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001)
    J J Moes
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Int J Pharm 420:244-50. 2011
    ..790 ± 669 ngh/mL). The low inter-individual variability of docetaxel exposure (44%), the dosing accuracy, and the absence of ethanol and polysorbate are major advantages of ModraDoc001 15 mg capsules over docetaxel premix solution...
  46. ncbi request reprint Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview
    C M F Kruijtzer
    Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Oncologist 7:516-30. 2002
    ..Future randomized studies will, hopefully, confirm that this strategy for oral treatment is at least as equally effective and safe as standard intravenous administration of these drugs...
  47. ncbi request reprint Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours
    M Crul
    Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Eur J Cancer 38:1615-21. 2002
    ..Therefore, MTD was established at 200 mg/day. The pharmacokinetic studies suggested dose proportionality...
  48. doi request reprint Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity
    J G C van Hasselt
    Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Pharmacol Ther 90:126-32. 2011
    ..9% increase in sensitivity (decrease in EC₅₀) at the maximum cumulative anthracycline dose. The developed population PK-PD model may be used to establish optimal treatment and cardiac monitoring strategies for trastuzumab...
  49. ncbi request reprint Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin
    Ch van Kesteren
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Anticancer Drugs 14:487-502. 2003
    ..The present review describes the development of ET-743, highlighting chemical properties, mode of action, metabolism and preclinical and clinical studies...
  50. ncbi request reprint Therapeutic drug monitoring of non-anticancer drugs in cancer patients
    M Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Methods Find Exp Clin Pharmacol 26:531-45. 2004
    ..In all cases, treating physicians have to consider the variability in patient age, disease stage, comedication, organ function and protein level to weigh the pros and cons of TDM in the individual cancer patient...
  51. ncbi request reprint Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry
    S A Veltkamp
    Division of Experimental Therapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
    J Mass Spectrom 41:1633-42. 2006
    ..18 ng/0.648 mg protein = 0.047 ng/10(6) cells or 94 fmol/10(6) cells). This highly sensitive assay is capable of quantifying about 200-fold lower concentrations of dFdCTP in human PBMCs than currently available methods...
  52. ncbi request reprint Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry
    I E L M Kuppens
    Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Biomed Chromatogr 19:355-61. 2005
    ..25 ng/mL. The assay was applied successfully in several clinical and pharmacological studies with docetaxel...
  53. doi request reprint Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma
    C M Nijenhuis
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands Electronic address
    J Chromatogr B Analyt Technol Biomed Life Sci 940:121-5. 2013
    ..A quantitative method was developed and validated for the quantification of olaparib in human plasma. The method could successfully be applied for the pharmacokinetic quantification of olaparib in cancer patients treated with olaparib. ..
  54. doi request reprint Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue
    N A G Lankheet
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Bioanalysis 4:2563-77. 2012
    ....
  55. pmc A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
    N E Schoemaker
    Department of Medical Oncology, Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Br J Cancer 87:608-14. 2002
    ..Haematological toxicity was relatively mild, but serious bladder toxicity was encountered which is typical for camptothecin and was found dose limiting...
  56. ncbi request reprint Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry
    E Stokvis
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    J Mass Spectrom 39:277-88. 2004
    ..We believe that the method described in this paper using an alkaline mobile phase in combination with a basic stable analytical column may also be generally useful for the bioanalysis of other basic drugs...
  57. ncbi request reprint Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance
    E Stokvis
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Biomed Chromatogr 18:400-2. 2004
    ..Similar results can be expected for other LC-MS/MS assays. Therefore, we emphasize the need for an SIL internal standard for accurate and precise LC-MS/MS assays of drugs in biological matrices...
  58. doi request reprint Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry
    A Kort
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 925:117-23. 2013
    ..In conclusion, this method can be applied to support clinical pharmacokinetic studies with the novel anticancer drug cabazitaxel...
  59. ncbi request reprint Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918
    C M F Kruijtzer
    Department of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 20:2943-50. 2002
    ..GF120918 is a potent inhibitor of BCRP and P-gp. The aim was to increase the bioavailability of topotecan by GF120918...
  60. pmc Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study
    M Joerger
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Br J Clin Pharmacol 64:622-33. 2007
    ..To assess quantitatively the safety and pharmacology of paclitaxel in patients with moderate to severe hepatic impairment...
  61. doi request reprint Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques
    S F Teunissen
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    J Pharm Biomed Anal 55:518-26. 2011
    ..In total, 19 metabolites have been identified in these serum samples. Additionally a synthetic method for the preparation of the putative metabolite 3',4'-dihydroxytamoxifen is described...
  62. doi request reprint Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices
    A C Dubbelman
    Department of Clinical Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 879:1149-55. 2011
    ..5 and 5 months, respectively. In conclusion, the validation results show that the assays are specific and accurate and can therefore adequately be applied to support clinical studies of eribulin...
  63. pmc Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
    J J M A Hendrikx
    1 Department of Pharmacy and Pharmacology, Slotervaart Hospital, PO 90440, 1006 BK Amsterdam, The Netherlands 2 Division of Molecular Oncology, The Netherlands Cancer Institute, PO 90203, 1006 BE Amsterdam, The Netherlands
    Br J Cancer 110:2669-76. 2014
    ..The resulting low oral bioavailability can be boosted by co-administration of P-gp or CYP3A4 inhibitors...
  64. pmc Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients
    M Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, and Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, The Netherlands
    Br J Clin Pharmacol 62:71-80. 2006
    ..To characterize determinants of the elimination of methotrexate (MTX) and 7-hydroxy-methotrexate (7-OH-MTX) in patients receiving high-dose MTX therapy (HDMTX)...
  65. doi request reprint Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry
    N A G Lankheet
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, Amsterdam, The Netherlands
    Biomed Chromatogr 27:466-76. 2013
    ..1%) and precision (10.0%) for all analytes. This method was successfully applied for routine therapeutic drug monitoring purposes in patients treated with the investigated TKIs...
  66. doi request reprint Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?
    C M Nijenhuis
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Cancer Treat Rev 39:305-12. 2013
    ..Subsequently the elucidation of these mechanisms resulted in the development of rational combination therapies to overcome toxicity and resistance. These combination therapies will be discussed...
  67. doi request reprint Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
    F E Stuurman
    Division of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Invest New Drugs 31:959-66. 2013
    ..CP-4126 acts as a prodrug for dFdC when given orally, but because of the poor absorption and the rapid pre-systemic metabolism the study was terminated early and no RD could be determined...
  68. doi request reprint Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel
    S L W Koolen
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Clin Pharmacol Ther 87:126-9. 2010
    ..Preclinical studies in Pgp-deficient and wild-type mice demonstrated that modulation of either Pgp or CYP3A resulted in high systemic exposure to docetaxel or paclitaxel. This concept could successfully be translated to clinical trials...
  69. ncbi request reprint DNA-based drug interactions of cisplatin
    M Crul
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Treat Rev 28:291-303. 2002
    ..In this paper, we review the pre-clinical and clinical studies investigating the observed interactions between cisplatin, the antimetabolites, taxanes, and topoisomerase inhibitors on the DNA level...
  70. pmc A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
    N E Schoemaker
    Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Br J Cancer 91:1434-41. 2004
    ..Irinotecan is an effective and safe second-line treatment for colorectal cancer. The schedules examined yielded equivalent results, indicating that there is no advantage of the prolonged vs short infusion schedules...
  71. doi request reprint Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry
    S F Teunissen
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 879:1677-85. 2011
    ..The applicability of the assay was demonstrated and it is now successfully used to support clinical studies in which patient-specific dose optimization is performed based on serum concentrations of tamoxifen metabolites...
  72. ncbi request reprint Hepatotoxicity and metabolism of trabectedin: a literature review
    J H Beumer
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Pharmacol Res 51:391-8. 2005
    ..Monitoring of plasma levels of liver enzymes ensures safe use of trabectedin in the clinic. Future investigations must be aimed at elucidating the mechanism of trabectedin hepatotoxicity...
  73. ncbi request reprint Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry
    E E M Brouwers
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    Anal Bioanal Chem 382:1484-90. 2005
    ..The validated ranges of quantification were 0.10-400 micromol L(-1) for human pUF and 0.50-400 micromol L(-1) for plasma. The assay is now successfully used to support pharmacokinetic studies of cancer patients treated with oxaliplatin...
  74. doi request reprint Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry
    J J M A Hendrikx
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Rapid Commun Mass Spectrom 27:1925-34. 2013
    ..We now describe an approach to quantify docetaxel metabolites in human plasma by liquid chromatography/tandem mass spectrometry (LC/MS/MS) using docetaxel calibration standards...
  75. doi request reprint Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring
    Nienke A G Lankheet
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ther Drug Monit 35:168-76. 2013
    ..To support TDM, a method for determination of sunitinib and its active metabolite (N-desethyl sunitinib) has been developed and validated...
  76. ncbi request reprint Pharmacokinetic-pharmacodynamic guided trial design in oncology
    Ch van Kesteren
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervnaart Hospital, Amsterdam, The Netherlands
    Invest New Drugs 21:225-41. 2003
    ..The application of PK-PD modeling in each separate stage of (pre)clinical drug development of anticancer agents is discussed. The implementation of this approach is illustrated with the clinical development of docetaxel...
  77. doi request reprint Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine
    A C Dubbelman
    Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 893:92-100. 2012
    ..These methods were successfully applied to evaluate the pharmacokinetic profile of bendamustine and its metabolites in cancer patients treated with bendamustine...
  78. doi request reprint Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis
    L A Devriese
    Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Lung Cancer 75:242-7. 2012
    ..CTCs may not only serve as a prognostic marker in selected tumor types, but may also be useful as pharmacodynamic marker in drug development...
  79. pmc A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer
    T J Molloy
    Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Cancer 104:1913-9. 2011
    ..The detection of circulating tumour cells (CTCs) has been linked with poor prognosis in advanced breast cancer. Relatively few studies have been undertaken to study the clinical relevance of CTCs in early-stage breast cancer...
  80. ncbi request reprint [The concomitant use of radiotherapy and chemotherapy for the treatment of solid malignant tumors]
    H Bartelink
    Afd Radiotherapie, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, Plesmanlaan 121, 1066 CX Amsterdam
    Ned Tijdschr Geneeskd 146:504-8. 2002
    ..Major further improvement can be expected from the design and use of new drugs that influence the pathways leading to cell death after irradiation...
  81. ncbi request reprint Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients
    Markus Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Basic Clin Pharmacol Toxicol 99:133-40. 2006
    ..Significant alterations of the free fraction of phenytoin and free phenytoin by co-administration of valproic acid or carbamazepine suggest therapeutic drug monitoring of free phenytoin to be of potential benefit in cancer patients...
  82. ncbi request reprint Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population
    T M Bosch
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Mol Diagn Ther 10:175-85. 2006
    ....
  83. ncbi request reprint Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application
    Isa E L M Kuppens
    Department of Medical Oncology, Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Invest 23:443-64. 2005
    ..Both are good examples of improvement of oral drug bioavailability by temporary inhibition of drug transporters in the gut epithelium...
  84. pmc Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
    N G L Jager
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 133:793-8. 2012
    ..We emphasize the use of highly selective LC-MS/MS methods for the quantification of tamoxifen and its metabolites in biological samples...
  85. ncbi request reprint Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice
    M L H Vlaming
    Division of Experimental Therapy, The Netherlands Cancer Institute, Division of Experimental Therapy, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Pharmacol Exp Ther 318:319-27. 2006
    ..Our results demonstrate that the Mrp2-/- mouse provides a valuable tool for studies of the impact of Mrp2 on behavior of drugs and other toxins, especially when combined with other ABC transporter knockout mice...
  86. ncbi request reprint SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity
    M C W Gast
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Cancer Biomark 2:235-48. 2006
    ..This finding stresses that, when reporting on a potential biomarker, confirmation of both robustness and validity is essential in obtaining its true clinical applicability...
  87. doi request reprint Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
    M H G Langenberg
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Ann Oncol 22:2508-15. 2011
    ..This phase I study investigated telatinib, an oral tyrosine kinase inhibitor targeting VEGFR-2, combined with bevacizumab, in adults with solid tumors...
  88. doi request reprint Ciprofloxacin strongly inhibits clozapine metabolism: two case reports
    E E M Brouwers
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Drug Investig 29:59-63. 2009
    ..This might cause severe adverse effects. We advise using another antibacterial agent or reducing the clozapine dose and monitoring clozapine levels when this antipsychotic agent is used in combination with ciprofloxacin...
  89. pmc Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry
    E E M Brouwers
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, and Department of Clinical Pharmacology and Pharmacy, Free University Medical Centre, Amsterdam, The Netherlands
    Int Arch Occup Environ Health 80:689-99. 2007
    ..To develop, validate, and apply a method for the determination of platinum contamination, originating from cisplatinum, oxaliplatinum, and carboplatinum...
  90. ncbi request reprint The combined use of radiotherapy and chemotherapy in the treatment of solid tumours
    H Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 38:216-22. 2002
    ..Examples include topoisomerase 1 (topo1) inhibitors, alkyl-lysophospholipids, epidermal growth factor receptor (EGFR) receptor inhibitors...
  91. ncbi request reprint Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies
    J H M Schellens
    Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam
    Invest New Drugs 20:83-93. 2002
    ..Prospective implementation of large scale population pharmacokinetic-dynamic analysis is feasible and important to establish whether interpatient variability in drug exposure is a major determinant of toxicity or activity...
  92. doi request reprint Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review
    S F Teunissen
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Anal Chim Acta 683:21-37. 2010
    ..This review can be used as a resource for method transfer and development of analytical methods used to support pharmacokinetic and pharmacodynamic studies of tamoxifen and its phase I metabolites...
  93. ncbi request reprint Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors
    M Crul
    The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam
    Eur J Drug Metab Pharmacokinet 27:61-5. 2002
    ..81-1.09 and 0.83-1.03, which is within the critical range for bioequivalence of 0.80-1.25. In conclusion, the established pharmacokinetic parameters demonstrate that the capsule and tablet formulations of R115777 are interchangeable...
  94. ncbi request reprint In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood
    H J G D van den Bongard
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Anticancer Drugs 14:405-10. 2003
    ..In conclusion, E7070 in whole blood is preferentially bound to RBC and exhibits high plasma protein binding. The non-linear distribution of E7070 in humans can be caused, in part at least, by saturable binding of E7070 to RBC...
  95. doi request reprint Propofol extravasation in a breast cancer patient
    E J M Huijbers
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, Amsterdam, The Netherlands
    J Oncol Pharm Pract 14:195-8. 2008
    ..Propofol extravasation did not result in tissue necrosis in this case. AC chemotherapy could be administered safely 3 days after propofol extravasation...
  96. doi request reprint The Dutch vision of clinical pharmacology
    J H M Schellens
    Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Pharmacol Ther 85:366-8. 2009
    ..The Dutch Society for Clinical Pharmacology and Biopharmacy offers answers to these questions and presents a new model for clinical pharmacology...
  97. doi request reprint Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial
    Annelies H Boekhout
    The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Division of Clinical Pharmacology, Amsterdam, The Netherlands
    J Clin Oncol 29:3862-8. 2011
    ..Additional analyses of the hot flash score over the full 12 weeks of treatment were performed...
  98. pmc Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism
    Maarten J Deenen
    The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, The Netherlands
    Oncologist 16:992-1005. 2011
    ..Based on the literature reviewed, opportunities for patient-tailored anticancer therapy are proposed...
  99. pmc Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects
    Maarten J Deenen
    Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Oncologist 16:1006-20. 2011
    ..Potential implications and opportunities for patient and drug selection for genotype-driven anticancer therapy are outlined...
  100. pmc Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism
    Maarten J Deenen
    Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Oncologist 16:820-34. 2011
    ..Based on the literature reviewed, opportunities for patient-tailored anticancer therapy are presented...
  101. ncbi request reprint Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer
    F Caponigro
    EORTC Early Clinical Studies Group, New Drug Development Program, Brussels, Belgium
    Eur J Cancer 38:70-4. 2002
    ..Despite the good toxicity profile, these results do not support further trials with XR 5000 in metastatic colorectal cancer...